Published Date: 21-Feb-2023
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Protein A Resin Market size is expected to reach $1.9 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
The Agarose-based segment acquired maximum revenue share in the Global Protein A Resin Market by Product Type 2021 thereby, achieving a market value of $840 million by 2028. This is credited to the high binding accuracy to attach ligands to the proteins in contrast to the other matrices. However, the agarose-based protein A resins have improved mechanical strength, better longevity, and a high capability to combine metal dopant absorption at suitable pH. This tendency will drive the segment's growth over the estimated period.
The Academic Research Institutes segment is showcasing a CAGR of 6.6% during (2022 - 2028). This is because of the rising government funding for R&D globally and healthcare expenditure and the rising capacity of mAbs, therapeutics, prevention of outbreaks, and techniques for disease surveillance. Besides this, the enhancements in hospital examination capacities in post-pandemic and the accessibility of high throughput examination abilities will significantly boost the market growth for the protein A resins in this segment.
The Recombinant segment is leading the Global Protein A Resin Market by Type 2021 thereby, achieving a market value of $1,000 million by 2028. It is utilized in improving the sensitivity of alkaline solutions and increasing their solubility. The recombinant protein A resins ligand is combined with agarose to provide a high binding ability to immunoglobulin in immunoglobulin fragmentation. It has a more certain binding ability. Thus, the increasing demand for recombinant protein resins in the pharmaceutical business is because of its enhancing technological developments for the drug discovery procedure.
The Immunoprecipitation segment has shown the growth rate of 7.4% during (2022 - 2028). IP (protein immunoprecipitation) is a small-extent affinity purification method that utilizes particular immobilized antibodies to alienate the selected antigens. Solid assists like magnetic particles and agarose resin disable the antibodies used in IP. The sector’s development is the result of the usage of immunoprecipitation in the R&D segment prospering through the biotechnology & biopharmaceutical businesses.
The North America market dominated the Global Protein A Resin Market by Region 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $755.7 million by 2028. The Europe market is experiencing a CAGR of 5.7% during (2022 - 2028). Additionally, The Asia Pacific market would display a CAGR of 7% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/protein-a-resin-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of General Electric (GE) Co. (GE Healthcare), Repligen Corporation, PerkinElmer, Inc, Thermo Fisher Scientific, Inc., Merck Millipore (Merck Group), Genscript Biotech Corporation, Agilent Technologies, Inc., Abcam plc, and Novasep Holdings SAS (Azulis Capital).
By Product Type
By End Use
Unique Offerings from KBV Research
North America Protein A Resin Market size & Opportunities 2022-2028
Europe Protein A Resin Market & Growth Forecast 2022-2028
Asia Pacific Protein A Resin Market Share & Industry Outlook to 2028
LAMEA Protein A Resin Market Growth, Trends & Forecasts 2022-2028